Formulation of Osimertinib Nano Lipid Carriers: Optimization, Characterization and Cytotoxicity Assessment

Release of molecules from nanocarriers

“…In agreement with the previous studies reviewed by Mircioiu et al, 7 recent studies (ref. [36][37][38][39][40][41][42][43][44][45][46][47] focused on various cargos and carriers show that a is often in the range from 0.45 to 0.85. As I have illustrated in Section III, the Weibull and Korsemeyer-Peppas expressions with this range of a can easily be reproduced by using the model under consideration with appreciable heterogeneity.…”

“…Several relevant recent studies (ref. [36][37][38][39][40][41][42][43][44][45][46][47] reporting typical values of a are as follows.…”

“…Such measurements are challenging and now lacking (see, e.g. , the already mentioned recent studies 36–47 ).…”

“…by exploring the specifics of the structure of micro-or nanocarriers and simultaneously measuring the rate of diffusion of drug or vaccine molecules inside and comparing the diffusion time scale with that of release. Such measurements are challenging and now lacking (see, e.g., the already mentioned recent studies [36][37][38][39][40][41][42][43][44][45][46][47] ).…”

Indole Antitumor Agents in Nanotechnology Formulations: An Overview

“…Using the Box–Behnken design with three independent variables, Gilani et al [ 113 ] optimized OSI nano lipid carriers (OSI-NLCs) that were evaluated for activity against lung cancer. The preparation of OSI-NLCs was carried out using the hot melt emulsification and sonication method.…”